Key Highlights

  • ADMA Biologics, Inc. (NASDAQ:ADMA) was up 25.52% at USD 13.16 during trading on November 5, 2026, according to published market data, with about 3.37 million shares traded.
  • Third quarter 2026 Revenue came to USD 141.1 million, a 5% increase, and ASCENIV revenue grew 31% to USD 124.7 million.
  • GAAP Net Income rose 37% to USD 49.9 million, while adjusted EBITDA went up 32% to USD 77.3 million.
  • Full-year 2026 guidance now points to adjusted net income of at least USD 180 million and adjusted EBITDA of at least USD 275 million.

Third Quarter Results and Raised Profit Targets

ADMA Biologics, Inc. (NASDAQ:ADMA) reported third quarter 2026 figures on November 4, 2026, and the Equity rallied in the following session. During trading on November 5, 2026, per published market data, the shares changed hands at USD 13.16, a 25.52% gain, with a market Capitalization around USD 2.95 billion, trailing diluted Earnings of USD 0.70 per share and a price-to-earnings ratio of 18.67. Revenue totaled USD 141.1 million, up 5%. ASCENIV, the company's immune globulin for primary immunodeficiency, produced USD 124.7 million, up 31%. GAAP net income hit USD 49.9 million, a 37% rise, and adjusted EBITDA of USD 77.3 million was 32% higher. Management lifted its adjusted net income and adjusted EBITDA outlook, while reaffirming revenue of at least USD 530 million.

Product Mix, Share Repurchases and Balance Sheet

Earnings outpaced sales because the product mix shifted toward ASCENIV, which carries higher pricing, while BIVIGAM, an older immune globulin, slid 35% to USD 15.4 million. Adjusted EBITDA, which removes interest, taxes, Depreciation and certain non-cash items, is the measure management relies on to show operating earnings power. In the quarter the company bought back 2.7 million shares, and 16.5 million year to date, roughly 6.3% of shares outstanding at December 31, 2025, and it expects to meet its goal of USD 200 million or more in repurchases for 2026. Chief executive Adam Grossman described the Business as converting rising ASCENIV Demand into meaningful earnings growth. Cash finished at USD 124.6 million, up from USD 87.6 million at the end of 2025.

Debt, Concentration and Reversal Hazards

Long-term Debt stood at USD 191.6 million plus a USD 4.2 million current portion, about USD 195.9 million combined by simple addition, versus roughly USD 72.1 million at the close of 2025, which means Buybacks were partly financed with borrowing. ADMA Biologics, Inc. (NASDAQ:ADMA) relies on ASCENIV for the bulk of its sales, heightening exposure to rival immune globulins, plasma Supply and reimbursement shifts. The 35% drop at BIVIGAM illustrates how fast a product can lose ground. Revenue growth of 5% is modest compared with the size of the share price move, and the trailing earnings change of negative 17.05% in published market data reflects a harder comparison base. Gains this large can reverse. Investors should keep an eye on ASCENIV trends, borrowing levels and the fourth quarter report.

Where Things Stand

The 25.52% advance in ADMA Biologics, Inc. (NASDAQ:ADMA) reflects solid reported results: ASCENIV up 31%, net income up 37% and higher adjusted profit guidance. The response is large for revenue growth of only 5%, implying the market is valuing Margin expansion and buybacks more than sales volume. Debt of about USD 195.9 million, reliance on a single product and the BIVIGAM decline are the main offsets. The next checkpoint is the fourth quarter report and any change to the 2026 goals.